Trial Summary
What is the purpose of this trial?This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
Eligibility Criteria
This trial is for people with a limited number of cancer spread sites (up to 5), who've had their primary tumor treated, and are not candidates for surgery. They should be in relatively good health otherwise, able to consent, and complete questionnaires in English. Pregnant women or those with certain medical conditions that make radiotherapy unsafe cannot join.Inclusion Criteria
I can take care of myself and am up and about more than half of the day.
My brain metastases have been approved for treatment by a specialized team.
I am not a candidate for surgery to remove my cancer as advised by my medical team.
My cancer has spread, and this was confirmed by tests.
My primary cancer was treated with intent to cure or controlled with prior therapy.
My non-brain cancer spot is no larger than 3cm if treated with a single radiation dose.
Exclusion Criteria
I have signs of pressure on my spinal cord.
My first chemotherapy fully eliminated the cancer that can be measured.
My cancer cannot be treated with the goal of removing it completely.
I have health conditions that prevent me from receiving radiation therapy.
My cancer has spread to my thigh bone and there's a high risk it might break.
I need surgery to relieve pressure in my brain from cancer.
I have ongoing fluid buildup due to cancer in the lining of my lung.
Treatment Details
The study tests Stereotactic Ablative Body Radiotherapy (SABR) on patients with few metastatic cancer sites. It aims to assess the side effects and potential survival benefits of this targeted high-dose radiation therapy compared to other treatments.
1Treatment groups
Experimental Treatment
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy
Find a clinic near you
Research locations nearbySelect from list below to view details:
BC CancerPrince George, Canada
Loading ...
Who is running the clinical trial?
British Columbia Cancer AgencyLead Sponsor